Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study

BMJ (Online)

Volumn 354, Issue , 2016, Pages

  Fleischman, William ^a   Agrawal, Shantanu ^b   King, Marissa ^c   Venkatesh, Arjun K ^d   Krumholz, Harlan M ^d   McKee, Douglas ^e   Brown, Douglas ^b   Ross, Joseph S ^d  

^a ROBERT WOOD JOHNSON FOUNDATION   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c YALE SCHOOL OF MANAGEMENT   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; DRUG MARKETING; HUMAN; MEDICAL FEE; MEDICAL PRACTICE; MEDICAL SPECIALIST; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; CLINICAL PRACTICE; ECONOMICS; GIFT GIVING; MEDICARE; PHYSICIAN;

ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; GIFT GIVING; HUMANS; HYPOGLYCEMIC AGENTS; MEDICARE PART D; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84985023460     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i4189     Document Type: Article

References (39)

1. Centers for Medicare & Medicaid Services. Open Payments Data Summary. OpenPaymentsData.CMS.gov https://openpayments data.cms.gov/summary (accessed 2 Aug 2016)
2. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med 2013;28:1064-71. doi:10.1007/s11606-013-2361-0
3. Halperin EC, Hutchison P, Barrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys 2004;59:1477-83. doi:10.1016/j. ijrobp.2004.01.052
4. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110:551-7. doi:10.1016/ S0002-9343(01)00660-X
5. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80. doi:10.1001/jama.283.3.373
6. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians prescribing: a systematic review. PLoS Med 2010;7:e1000352. doi:10.1371/journal.pmed.1000352
7. King M, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place 2013;20:32-8. doi:10.1016/j.healthplace.2012.11.007
8. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. Theres no such thing as a free lunch. Chest 1992;102:270-3. doi:10.1378/chest.102.1.270
9. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988;8:13-20. doi: 10.1002/ chp.4750080104
10. Chren MM, Landefeld CS. Physicians behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-9. doi:10.1001/jama.1994.03510330062035
11. Ornstein C, Grochowski Jones R. Vying for Market Share, Companies Heavily Promote "Me Too" Drugs. Pro Publica 2015. http://bit. ly/1xScCd2 (accessed 2 Aug 2016)
12. Donohue JM, Morden NE, Gellad WF, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med 2012;366:530-8. doi:10.1056/NEJMsa1104816
13. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008;336:1402-3. doi:10.1136/ bmj.39575.675787.651
14. Steensma DP. Key Opinion Leaders. J Clin Oncol 2015;33:3213-4. doi:10.1200/JCO.2015.63.1275
15. The Dartmouth Institute for Health Policy and Clinical Practice. The Dartmouth Atlas of Health Care. http://bit.ly/28zQV46 (accessed 2 Aug 2016)
16. Hoadley J, Summer L, Hargrave E, Cubanski J, Newman T. Medicare Part D in Its Ninth Year. Kaiser Family Foundation; 2014. http://kaiserf. am/1VpeYue (accessed 2 Aug 2016)
17. Centers for Medicare & Medicaid Services. Monthly Contract and Enrollment Summary Report http://go.cms.gov/2avyBTl (accessed Aug 2016).
18. 2014 Physician Specialty Databook 2014. Association of American Medical Colleges; 2014. http://bit.ly/1td3hiO (accessed 2 Aug 2016)
19. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216-doi:10.1001/jama.297.11.1216.
20. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. Mayo Clin Proc 2016;91:84-96. doi:10.1016/j.mayocp.2015.10.016
21. Ahmed R, Chow EK, Massie AB, et al. Where the Sun Shines: Industrys Payments to Transplant Surgeons. Am J Transplant 2016;16:292-300. doi:10.1111/ajt.13427
22. Jairam V, Yu JB. Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database. Int J Radiat Oncol Biol Phys 2016;94:19-26. doi:10.1016/j.ijrobp.2015.09.004
23. Rathi VK, Samuel AM, Mehra S. Industry ties in otolaryngology: initial insights from the physician payment sunshine act. Otolaryngol Head Neck Surg 2015;152:993-9. doi:10.1177/0194599815573718
24. Chang JS. The Physician Payments Sunshine Act: data evaluation regarding payments to ophthalmologists. Ophthalmology 2015;122:656-61. doi:10.1016/j.ophtha.2014.11.003
25. Cvetanovich GL, Chalmers PN, Bach BR Jr. Industry Financial Relationships in Orthopaedic Surgery: Analysis of the Sunshine Act Open Payments Database and Comparison with Other Surgical Subspecialties. J Bone Joint Surg Am 2015;97:1288-95. doi:10.2106/JBJS.N.01093
26. Fleischman W, Ross JS, Melnick ER, Newman DH, Venkatesh AK. Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments Data. Ann Emerg Med 2016;68:153-158.e4. doi:10.1016/j.annemergmed.2016.01.014
27. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Intern Med 2016;176:763-8. doi:10.1001/jamainternmed.2016.1709
28. Waud DR. Pharmaceutical promotions-a free lunch? N Engl J Med 1992;327:351-3. doi:10.1056/NEJM199207303270511
29. Kassirer JP. A piece of my mind: financial indigestion. JAMA 2000;284:2156-7. doi:10.1001/jama.284.17.2156
30. Campbell EG. Doctors and drug companies-scrutinizing influential relationships. N Engl J Med 2007;357:1796-7. doi:10.1056/ NEJMp078141
31. Campbell D, Sharkey B. Ready Or Not, Full Speed Ahead For The Global Transparency Movement. Porzio LifeSciences; 2015. http://bit. ly/1S2VQP3 (accessed 2 Aug 2016)
32. European Federation of Pharmaceutical Industries and Associations. EFPIA - The EFPIA Code. http://transparency.efpia.eu/the-efpia-code-2 (accessed 2 Aug 2016)
33. Atwill N. France: New Law on Drug Safety | Global Legal Monitor. Library of Congress; 2012. http://1.usa.gov/1YoaGau (accessed 2 Aug 2016)
34. Ornstein C, Sagara E, Grochowski Jones R. As Full Disclosure Nears, Doctors Pay for Drug Talks Plummets. Pro Publica 2014. http://bit. ly/1hIMNEc (accessed 2 Aug 2016)
35. National Center for Health Statistics (US). Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville (MD): National Center for Health Statistics (US); 2014. http://1.usa.gov/1w2lsqX (accessed 2 Aug 2016)
36. Narayanan S, Manchanda P, Chintagunta PK. Temporal Differences in the Role of Marketing Communication in New Product Categories. J Mark Res 2005;42:278-90. doi:10.1509/jmkr.2005.42.3.278
37. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311-20. doi:10.1016/S0149-2918(01)80110-7
38. Robinson WS. Ecological correlations and the behavior of individuals. Int J Epidemiol 2009;38:337-41. doi:10.1093/ije/dyn357
39. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescriptiondrug utilization and spending. N Engl J Med 2003;349:2224-32. doi:10.1056/NEJMsa030954